^
Association details:
| Biomarker: | TCF7L2 mutation |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Tyvyt (sintilimab) (PD1 inhibitor) + Fruzaqla (fruquintinib) (VEGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Fruquintinib combination with sintilimab in refractory metastatic colorectal cancer patients in China.
Published date:
05/13/2020
Excerpt:
PFS was significantly worse in patients with the following mutations: AMER1 (p=0.0073), DNMT3A (p=0.0075), ETV5 (p=0.012), EWSR1 (p=0.016), FANCA (p=0.019), IKBKE (p=0.0073), NOTCH1 (p=0.015), STAG2 (p=0.012) and TCF7L2 (p=0.0073)….Fruquintinib combined with Sintilimab seemed not resulted in a significant increase in ORR, DCR and OS in refractory mCRC.
DOI:
10.1200/JCO.2020.38.15_suppl.4028
